Class: Alpha-glucosidase inhibitor
- Tablets 25 mg
- Tablets 50 mg
- Tablets 100 mg
Inhibits intestinal enzymes that digest carbohydrates, thereby reducing carbohydrate digestion after meals, which lowers postprandial glucose elevation in diabetics.
Absorption is saturable at high doses (ie, 25 mg dose is completely absorbed vs 100 mg dose is only 50% to 70% absorbed). T max is 2 to 3 h.
Distributes primarily into the extracellular fluid. Less than 4% is protein bound and Vd is 0.18 L/kg.
Miglitol is not metabolized.
Eliminated by renal excretion as unchanged. More than 95% is recovered in the urine within 24 h. Plasma t ½ is approximately 2 h.
Special PopulationsRenal Function Impairment
Because miglitol is excreted primarily by the kidneys, accumulation is expected. However, dosage adjustment to correct the increased plasma concentrations is not feasible because miglitol acts locally.
Indications and Usage
Patients with NIDDM who have failed dietary therapy. May be used alone or in combination with sulfonylureas.
Diabetic ketoacidosis; inflammatory bowel disease; colonic ulceration; intestinal disorders of digestion or absorption; partial or predisposition to intestinal obstruction; conditions that may deteriorate as a result of increased intestinal gas production.
Dosage and AdministrationAdults
PO 25 mg 3 times daily at the start of each meal. After 4 to 8 wk can increase to 50 mg/dose for 3 mo. If glycosylated hemoglobin level not acceptable after 3 mo can increase at 100 mg 3 times daily (max dose).
Store at room temperature (59° to 86°F) in a tightly closed container, protected from moisture.
Drug InteractionsIntestinal absorbents (eg, charcoal), digestive enzymes
May lower efficacy of miglitol.Drugs that produce hyperglycemia (eg, corticosteroids, diuretics, thyroid preparations)
May lead to loss of glucose control.Ranitidine
Reduced ranitidine bioavailability.Propranolol
Reduced propranolol bioavailability.
Laboratory Test Interactions
Transient decreases in serum iron that are not associated with hemoglobin reduction or other changes in hematologic indices.
Abdominal pain; diarrhea; flatulence.
Category B .
Excreted in breast milk.
Safety and efficacy not established.
Miglitol not recommended if serum creatinine is more than 2 mg/dL.
Miglitol does not produce hypoglycemia; however, hypoglycemia may develop if used together with sulfonylureas. Use glucose (dextrose) and not cane sugar (table sugar) or fruits/fruit juices to treat hypoglycemia.
Loss of blood glucose control
Certain medical conditions (eg, surgery, fever, infection, or trauma) and drugs (eg, diuretics, corticosteroids, oral contraceptives) affect glucose control. In these situations, it may be necessary to adjust the dose of miglitol and other antidiabetic drugs.
Increased flatulence, diarrhea, abdominal discomfort.
- Advise patient to take the drug with the first bite of each meal. If necessary, it may be taken during the meal if not taken with the first bite. Do not take after the meal is complete or if skipping a meal.
- Advise patient not to change the dose or dosing interval or discontinue the drug without consulting with health care provider.
- Encourage patient to continue to adhere to a regular exercise program and follow their diabetic meal plan.
- Counsel patient on proper monitoring of blood glucose.
- Advise women of childbearing age that this medication should not be used during pregnancy. Insulin is the preferred agent to control blood glucose.
- Advise patient family that “cane sugar” (sucrose or table sugar) or fruits or fruit juices should not be used to treat hypoglycemic reactions. Glucose (dextrose) or glucagon are necessary to increase blood sugar.
- Advise patient that GI adverse reactions (eg, gas, diarrhea, or abdominal discomfort) usually occur during the first few weeks of therapy but generally go away. Advise patient to inform health care provider if these effects persist or become intolerable.
Copyright © 2009 Wolters Kluwer Health.